CELC
Celcuity Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-40/100
Last price
71.25
▼ 2.37 (3.22%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
73.95
Prev close
73.62
Day high
76.29
Day low
70.32
Volume
1.56M
Market cap
$3.49B
P/E (TTM)
—
52W range
45.03 – 151.02
Day trading desk
Gap from prior close
+0.45%
Prior close 73.62
VWAP
71.68
-0.61% from price
Relative volume
2.24×
Unusually busy
Session range
13.67%
69.50 – 79.00
Position in range
18%
Near session low
ATR (14D)
4.75
6.67% of price
Prior day high
74.60
PDH
Prior day low
69.00
PDL
Bid / ask spread
—
Quote not published
Session volume
2.65M
Avg 1.18M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-7.92%
-9.9%
1M
-25.55%
-26.7%
3M
-34.57%
-39.1%
6M
-38.34%
-56.5%
YTD
-28.56%
-42.8%
1Y
+41.06%
+24.6%
3Y
+679.54%
+597.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CELC open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-2.99M
Net selling
Buy transactions
13
146.21K shares
Sell transactions
3
3.13M shares
Net transactions
+16
Buys less sells
Sell : buy shares
21.4 : 1
Heavily one-sided
Insider-held shares
5.01M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | SULLIVAN BRIAN F Chief Executive Officer |
STOCK | 80.00K | $0 | Direct |
| Aug 14, 26 | LAING LANCE G PH.D. Officer and Director |
STOCK | 20.00K | $0 | Direct |
| Aug 14, 26 | HAHNE VICKY Chief Financial Officer |
STOCK | 16.00K | $0 | Direct |
| Jul 14, 26 | BAKER BROS ADVISORS L.P. Unknown |
SELL | 3.10M | $317.75M | Indirect |
| Jun 5, 26 | DALVEY DAVID F Director |
STOCK | 1.53K | $0 | Direct |
| Jun 5, 26 | NIGON RICHARD J Director |
STOCK | 1.53K | $0 | Direct |
| Jun 5, 26 | BULLER RICHARD E Director |
STOCK | 1.53K | $0 | Direct |
| Jun 5, 26 | FURCHT LEO M.D. Director |
STOCK | 1.53K | $0 | Direct |
| Jun 5, 26 | ROMP CHARLES R Director |
STOCK | 1.53K | $0 | Direct |
| Jun 5, 26 | MURPHY POLLY A Director |
STOCK | 1.53K | $0 | Direct |
| Jun 2, 26 | LAING LANCE G PH.D. Officer and Director |
CONVERSION | 1.00K | $9.89K | Direct |
| May 19, 26 | BULLER RICHARD E Director |
STOCK | 1.03K | $0 | Direct |
| May 4, 26 | BULLER RICHARD E Director |
CONVERSION | 9.00K | $45.90K | Indirect |
| May 4, 26 | DALVEY DAVID F Director |
SELL | 25.00K | $3.52M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAKER BROS ADVISORS L.P. |
Unknown | — | Sale |
BULLER RICHARD E |
Director | 9.32K | Stock Award(Grant) |
DALVEY DAVID F |
Director | 66.53K | Stock Award(Grant) |
FURCHT LEO M.D. |
Director | 12.53K | Stock Award(Grant) |
HAHNE VICKY |
Chief Financial Officer | 37.81K | Stock Award(Grant) |
LAING LANCE G PH.D. |
Officer and Director | 1.27M | Stock Award(Grant) |
MURPHY POLLY A |
Director | 6.53K | Stock Award(Grant) |
NIGON RICHARD J |
Director | 80.56K | Stock Award(Grant) |
ROMP CHARLES R |
Director | 1.75K | Stock Award(Grant) |
SULLIVAN BRIAN F |
Chief Executive Officer | 3.20M | Stock Award(Grant) |
Fundamentals
Market cap$3.49B
Enterprise value$3.49B
Revenue (TTM)—
Gross profit—
EBITDA$-208.48M
Net income$-226.48M
EPS (TTM)$-4.17
Free cash flow$-72.00M
Total cash$754.04M
Total debt$754.39M
Book value / share$-0.26
Shares outstanding48.93M
Float29.72M
Short % of float34.83%
Dividend yield0.00%
Beta (5Y)0.11
Valuation & profitability ratios
Trailing P/E—
Forward P/E-890.63
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA-16.73
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-1433.70%
Return on assets-25.78%
Debt / equity—
Current ratio8.93
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $145.00M | $104.20M | $60.59M | $35.29M | +39.1% |
| Selling, general & admin | $27.20M | $9.06M | $5.64M | $4.10M | +200.1% |
| Total operating expense | $172.19M | $113.27M | $66.23M | $39.39M | +52.0% |
| Operating income | -$172.19M | -$113.27M | -$66.23M | -$39.39M | -52.0% |
| Net interest income | -$4.85M | $1.49M | $2.45M | -$978.95K | -425.9% |
| Pre-tax income | -$177.04M | -$111.78M | -$63.78M | -$40.37M | -58.4% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$177.04M | -$111.78M | -$63.78M | -$40.37M | -58.4% |
| Net income to common | -$177.04M | -$111.78M | -$63.78M | -$40.37M | -58.4% |
| Basic EPS | -3.79 | -2.83 | -2.69 | -2.64 | -33.9% |
| Diluted EPS | -3.79 | -2.83 | -2.69 | -2.64 | -33.9% |
| EBIT | -$159.89M | -$101.50M | -$58.45M | -$38.26M | -57.5% |
| EBITDA | -$159.73M | -$101.37M | -$58.31M | -$38.05M | -57.6% |
| Basic shares | 46.76M | 39.45M | 23.68M | 15.42M | +18.5% |
| Diluted shares | 46.76M | 39.45M | 23.68M | 15.42M | +18.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $165.70M | $22.52M | $30.66M | $24.57M | +636.0% |
| Cash & short-term investments | $441.50M | $235.10M | $180.58M | $168.59M | +87.8% |
| Total current assets | $465.66M | $244.57M | $190.59M | $175.19M | +90.4% |
| Property, plant & equipment | $550.00K | $552.00K | $628.80K | $506.56K | -0.4% |
| Total assets | $466.56M | $245.12M | $191.22M | $175.70M | +90.3% |
| Total current liabilities | $44.15M | $31.72M | $14.19M | $6.88M | +39.2% |
| Long-term debt | $321.85M | $97.73M | $37.04M | $34.98M | +229.3% |
| Total debt | $321.90M | $97.95M | $37.45M | $35.24M | +228.6% |
| Total liabilities | $366.00M | $129.50M | $51.45M | $41.93M | +182.6% |
| Retained earnings | -$448.90M | -$271.86M | -$160.08M | -$96.30M | -65.1% |
| Shareholder equity | $100.56M | $115.62M | $139.77M | $133.77M | -13.0% |
| Working capital | $421.51M | $212.85M | $176.40M | $168.31M | +98.0% |
| Net tangible assets | $100.56M | $115.62M | $139.77M | $133.77M | -13.0% |
| Shares issued | 48.24M | 37.14M | 25.51M | 21.67M | +29.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$177.04M | -$111.78M | -$63.78M | -$40.37M | -58.4% |
| Depreciation & amortisation | $167.00K | $130.00K | $142.77K | $210.92K | +28.5% |
| Stock-based compensation | $21.38M | $6.99M | $4.90M | $4.64M | +206.0% |
| Change in working capital | -$2.65M | $18.35M | $3.86M | -$1.19M | -114.5% |
| Operating cash flow | -$153.28M | -$83.47M | -$53.81M | -$36.01M | -83.6% |
| Capital expenditure | -$249.00K | -$250.00K | -$97.64K | -$158.77K | +0.4% |
| Investing cash flow | -$64.08M | -$63.07M | -$5.01M | -$144.03M | -1.6% |
| Financing cash flow | $360.55M | $138.39M | $64.91M | $120.33M | +160.5% |
| Free cash flow | -$153.53M | -$83.72M | -$53.91M | -$36.17M | -83.4% |
| End cash position | $165.70M | $22.52M | $30.66M | $24.57M | +636.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $31.08M | $33.06M | $37.63M | $34.91M | $36.41M | -6.0% |
| Selling, general & admin | $35.04M | $17.44M | $11.57M | $7.93M | $7.59M | +100.9% |
| Total operating expense | $66.12M | $50.51M | $49.20M | $42.85M | $44.01M | +30.9% |
| Operating income | -$66.12M | -$50.51M | -$49.20M | -$42.85M | -$44.01M | -30.9% |
| Net interest income | -$1.27M | -$2.33M | -$1.77M | -$955.00K | -$1.26M | +45.6% |
| Pre-tax income | -$78.86M | -$52.84M | -$50.97M | -$43.80M | -$45.27M | -49.2% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$78.86M | -$52.84M | -$50.97M | -$43.80M | -$45.27M | -49.2% |
| Net income to common | -$78.86M | -$52.84M | -$50.97M | -$43.80M | -$45.27M | -49.2% |
| Basic EPS | -1.44 | -0.97 | -0.97 | -0.92 | -1.04 | -48.5% |
| Diluted EPS | -1.44 | -0.97 | -0.97 | -0.92 | -1.04 | -48.5% |
| EBIT | -$73.44M | -$46.76M | -$44.81M | -$39.21M | -$42.06M | -57.1% |
| EBITDA | -$73.38M | -$46.71M | -$44.76M | -$39.17M | -$42.02M | -57.1% |
| Basic shares | 54.82M | 54.46M | 52.54M | 47.59M | 43.66M | +0.6% |
| Diluted shares | 54.82M | 54.46M | 52.54M | 47.59M | 43.66M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $182.05M | $145.19M | $165.70M | $74.25M | $46.35M | +25.4% |
| Cash & short-term investments | $754.04M | $387.06M | $441.50M | $454.98M | $168.39M | +94.8% |
| Total current assets | $775.84M | $408.93M | $465.66M | $475.50M | $183.10M | +89.7% |
| Property, plant & equipment | $1.72M | $632.00K | $550.00K | $507.00K | $488.00K | +171.8% |
| Goodwill & intangibles | $50.00M | — | — | — | — | — |
| Total assets | $828.22M | $410.16M | $466.56M | $476.00M | $183.59M | +101.9% |
| Total current liabilities | $86.87M | $33.21M | $44.15M | $38.79M | $39.94M | +161.6% |
| Long-term debt | $753.24M | $323.43M | $321.85M | $320.25M | $99.28M | +132.9% |
| Total debt | $754.38M | $323.44M | $321.90M | $320.35M | $99.42M | +133.2% |
| Total liabilities | $841.00M | $356.64M | $366.00M | $359.04M | $139.22M | +135.8% |
| Retained earnings | -$580.60M | -$501.74M | -$448.90M | -$397.92M | -$354.12M | -15.7% |
| Shareholder equity | -$12.78M | $53.52M | $100.56M | $116.96M | $44.38M | -123.9% |
| Working capital | $688.97M | $375.72M | $421.51M | $436.70M | $143.16M | +83.4% |
| Net tangible assets | -$62.78M | $53.52M | $100.56M | $116.96M | $44.38M | -217.3% |
| Shares issued | 48.92M | 48.35M | 48.24M | 43.27M | 38.91M | +1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$78.86M | -$52.84M | -$50.97M | -$43.80M | -$45.27M | -49.2% |
| Depreciation & amortisation | $59.00K | $47.00K | $49.00K | $41.00K | $40.00K | +25.5% |
| Stock-based compensation | $6.90M | $5.33M | $9.46M | $6.78M | $2.70M | +29.7% |
| Change in working capital | $3.13M | -$8.29M | $2.00M | -$7.70M | $4.24M | +137.8% |
| Operating cash flow | -$55.43M | -$55.06M | -$36.40M | -$44.82M | -$36.21M | -0.7% |
| Capital expenditure | -$136.00K | -$285.00K | -$53.00K | -$97.00K | -$39.00K | +52.3% |
| Investing cash flow | -$330.59M | $34.52M | $103.41M | -$257.61M | $65.86M | -1,057.7% |
| Financing cash flow | $422.87M | $34.00K | $24.44M | $330.32M | $232.00K | +1,243,647.1% |
| Free cash flow | -$55.56M | -$55.35M | -$36.45M | -$44.91M | -$36.25M | -0.4% |
| End cash position | $182.05M | $145.19M | $165.70M | $74.25M | $46.35M | +25.4% |
Options analytics
Put / call volume
0.75
Call-heavy session
Put / call open interest
0.13
Positioning, not flow
Max pain
60.00
-15.8% from spot
ATM implied vol
508.2%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
226
Contracts, this expiry
Put volume
170
Contracts, this expiry
Heaviest call OI
150.00
16 contracts
Heaviest put OI
105.00
3 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.08 | -1.07 | +0.9% |
| Mar 2026 | -0.89 | -0.86 | +3.4% |
| Dec 2025 | -1.01 | -0.73 | +27.7% |
| Sep 2025 | -0.96 | -0.78 | +18.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.51 | 2 | $1.56M | 0.0% |
| Next quarter | -0.82 | 2 | $21.43M | 0.0% |
| Current year | -4.39 | 2 | $22.80M | 0.0% |
| Next year | -0.08 | 2 | $324.34M | +1,322.8% |
Analyst targets & ownership
Mean target$156.91
High target$177.00
Low target$130.00
Implied upside120.22%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy3 / 9
Hold0
Sell / Strong sell0 / 0
Held by insiders10.23%
Held by institutions110.11%
Institutions holding366
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
76.75
-7.17% from price
SMA 20
80.45
-11.43% from price
SMA 50
86.86
-17.97% from price
SMA 100
95.66
-25.52% from price
SMA 200
104.16
-31.59% from price
EMA 12
77.25
-7.76% from price
EMA 26
81.61
-12.70% from price
EMA 50
86.37
-17.51% from price
RSI (14)
31.2
Neutral
MACD (12,26,9)
-4.37
Hist -0.80
ATR (14)
4.75
6.67% of price
Realised vol 30D
47.2%
Annualised
Bollinger upper
89.77
20, 2σ
Bollinger lower
71.13
20, 2σ
50 / 200 cross
Death
86.86 vs 104.16
Trend bias
Below 200
-31.59%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.25
More volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
47.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-50.9%
Peak to trough
Max drawdown 5Y
-72.4%
Peak to trough
ATR 14
4.75
6.67% of price
Beta (reported)
0.11
5Y monthly, from filing
Short interest
Shares short
11.36M
Prior 10.54M
Change vs prior
+7.8%
Shorts adding
% of float
34.83%
Heavily shorted
% of shares out
23.22%
Against total outstanding
Days to cover
14.1
Crowded exit
Float
29.72M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 26 | Needham | MAINTAINED | Buy | Buy |
| Sep 17, 26 | JP Morgan | INITIATED | — | Overweight |
| Aug 17, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 17, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 14, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 14, 26 | Stifel | MAINTAINED | Buy | Buy |
| Aug 14, 26 | Needham | MAINTAINED | Buy | Buy |
| Jul 15, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Jul 15, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 3, 26 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Jun 3, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jun 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-02
Corporate Changes & Voting Matters
8-K · 2026-09-30
Corporate Changes & Voting Matters
8-K · 2026-08-26
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-07-15
Corporate Changes & Voting Matters
8-K · 2026-06-08
Corporate Changes & Voting Matters
8-K · 2026-06-02
Corporate Changes & Voting Matters
8-K/A · 2026-05-20
Headlines
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
GlobeNewswire · 2d ago
Celcuity (CELC) Dropped, So What Is Behind Its Latest Move?
Simply Wall St. · 4d ago
Celcuity Appoints David Gryska To Its Board Of Directors
GlobeNewswire · 5d ago
Why Celcuity Stock Was a Winner on Wednesday
Motley Fool · 6d ago
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
GlobeNewswire · 7d ago
Is Celcuity (CELC) Stock a Buy?
Insider Monkey · 9d ago
JPMorgan Initiates Celcuity With Overweight Rating, $157 Price Target
MT Newswires · 20d ago
Celcuity To Participate in Upcoming Investor Conferences
GlobeNewswire · 36d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.